Could cause temporary or reversible harm; serious harm is unlikely.
Failed Impurities/Degradation Specifications.
| Brand name | CISPLATIN |
| Generic name | CISPLATIN |
| Active ingredient(s) | CISPLATIN |
| Distributed by / for | Accord Healthcare Inc., Durham, NC 27703 |
| NDC | 16729-288-38 |
| Full product label | Cisplatin Injection, 100mg/100mL (1mg/mL), For Intravenous Use, 100 mL Multiple Dose Vial, Rx Only, Manufactured for: Accord Healthcare Inc., Durham, NC 27703. Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad 382 213, India. Mfg. Lic. No.: G/28/1336, NDC 16729-288-38 |
| Recalling firm | ACCORD HEALTHCARE, INC. |
| Distribution | Nationwide within the United States and PR |
| Quantity | 11,214 vials |
| Recall initiated | 2024-10-01 |
| Report date | 2024-10-23 |
| Recall completed | 2026-02-23 |
| Recall number | D-0010-2025 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Raleigh NC United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗